MD&A · 2025
In this section4 topics
Overview of Operations
Overview of Operations
Performance Overview and Market Adaptation
Despite facing a market correction and costs associated with branch expansion in 2025, the Company maintained its financial strength with a Debt-to-Equity (D/E) Ratio of only 0.14 times. At the same time, the Company enhanced its profitability potential by increasing the average treatment package price by 5.31 percent. Looking forward to 2026, the Company will focus on a strategy of expanding its customer base to international markets and high-margin innovations to create continuous returns for shareholders.
Financial Highlights and Capital Structure
The Company reported a net profit attributable to the owners of the parent company of Baht 22.40 million. The decrease in profit was mainly due to the recognition of fixed costs and depreciation from branch expansions (Rama 9 International and Ubon Ratchathani) totaling more than Baht 29.36 million. However, the Company remains financially strong with a D/E Ratio of only 0.14 times and a Quick Ratio of 2.36 times.
Key Risk Analysis
The Company recognizes challenges that may affect performance, including:
Volatility of demand from foreign customers: Facing challenges from the Chinese government’s policy to support domestic infertility treatment, which directly impacts international market expansion.
Cost burden from business expansion: Risks related to managing the Utilization Rate of the new branch (Rama 9 International) to reach the break-even point amidst increasing fixed costs.
Economic conditions and domestic purchasing power: Pressures from high household debt, which may cause domestic customers to delay decisions regarding high-cost services.
Strategic Direction and Operational Plan for 2026 ( Outlook 2026)
To return performance to target levels and create sustainable growth, the Company has established the following proactive strategies:
Optimization of Assets Utilization: Accelerate proactive marketing, especially international marketing both offline and online, to increase the utilization rate of the Rama 9 branch to its full potential.
Strategic Market Expansion: Expand the customer base to high-potential countries (Strategic Markets) such as CLMV countries, the Middle East, and Europe.
Synergetic Partnership: Integrate cooperation with hospital networks and clinic partners both in Bangkok and major cities nationwide.
Inorganic Growth & Diversification: Seek investment opportunities in related new businesses to extend and strengthen the core business.
High-Margin Innovation: Focus on growth through high-margin services and advanced technologies such as Oocyte Freezing, embryo genetic testing (PGT-A), and other new technologies in the future.
Operating Results & Financial Condition
Operating Results & Profitability
Operating Results (For Q4/2025 and Year 2025)
Consolidated Financial Statements: Profit and Loss

Quarterly Performance Analysis
Revenue Structure

Remark:
(1) Revenue from ICSI service and other services, including Testicular Sperm Extraction (TESE), Eggs/Sperm/Embryo Freezing, Endometrial Receptivity Analysis (ERA TEST), and Blastocyst culture (Closed system) through Geri plus.
(2) Revenue from preliminary examination before counseling or treatment includes consultation fee, laboratory examination fee, and Ultrasound and Endoscopy fee. (ther revenue includes interest revenue.Revenue from ultrasound/endoscopy, etc.
(3) Other income includes interest income from bank deposits.

Remark:
(1) Revenue from ICSI service and other services, including Testicular Sperm Extraction (TESE), Eggs/Sperm/Embryo Freezing, Endometrial Receptivity Analysis (ERA TEST), and Blastocyst culture (Closed system) through Geri plus.
(2) Revenue from preliminary examination before counseling or treatment includes consultation fee, laboratory examination fee, and Ultrasound and Endoscopy fee. (ther revenue includes interest revenue.
Revenue from services: In the fourth quarter of 2025, the Company’s service revenue amounted to Baht 81.22 million. This represents a decrease of Baht 6.95 million or 7.88 percent compared to the fourth quarter of 2024, which had service revenue of Baht 88.17 million. This decline resulted from a slowdown in the number of infertility patients seeking services. Furthermore, revenue decreased by Baht 10.44 million or 11.39 percent compared to the third quarter of 2025, which had service revenue of Baht 91.66 million, also due to a decrease in the number of patients.
For the year 2025, the Company reported service revenue of Baht 352.99 million, a decrease of Baht 18.77 million or 5.05 percent compared to 2024, which recorded service revenue of Baht 371.76 million. This decline was due to a decrease in the number of patients seeking treatment, consistent with the number of egg retrieval cycles in 2025, which fell by 91 cycles or 9.84 percent year-over-year. However, service revenue decreased by only 5.05 percent because it was offset by a price adjustment in infertility treatment programs.
The average price increased from Baht 0.40 million per egg retrieval cycle in 2024 to Baht 0.42 million per cycle in 2025, representing a price increase of 5.31 percent, as shown in the chart below:
The number of egg retrieval cycles from 2022 through the third quarter of 2025 is as follows:

Cost of services: In the fourth quarter of 2025, the Company’s cost of services amounted to Baht 47.30 million, representing an increase of Baht 0.65 million or 1.39 percent compared to the fourth quarter of 2024, which had a cost of services of Baht 46.65 million. This increase was primarily due to:
Depreciation of buildings, building improvements, and medical equipment: Increased by Baht 3.19 million due to the opening of the Rama 9 International branch.
Cost of medicines and medical supplies: Decreased by Baht 2.03 million, consistent with the decline in service revenue.
Doctor and Embryologist professional fees: Decreased by Baht 1.41 million, consistent with the decline in service revenue.
Utility expenses: Increased by Baht 0.78 million from expenses related to the Rama 9 International branch, such as electricity, security services, and janitorial staff.
Furthermore, the cost of services decreased by Baht 4.98 million or 9.53 percent compared to the third quarter of 2025, which had a cost of services of Baht 52.28 million. This decrease was driven by lower costs of medicines and medical supplies, as well as reduced doctor and medical technician fees, both of which were consistent with the decline in service revenue. Additionally, personnel-related expenses decreased due to adjustments in the employee bonus provision.
For the year 2025, the Company’s cost of services amounted to Baht 205.84 million, an increase of Baht 12.41 million or 6.41 percent compared to 2024, which had a cost of services of Baht 193.43 million. This was primarily due to:
Depreciation of buildings, building improvements, and medical equipment: Increased by Baht 18.71 million due to the opening of the Rama 9 International branch.
Personnel expenses: Increased by Baht 2.35 million from the addition of medical and nursing staff, as well as medical technicians.
Utility expenses: Increased by Baht 3.75 million from costs associated with the Rama 9 International branch, such as electricity, security services, and janitorial services.
Cost of medicines and medical supplies: Decreased by Baht 5.26 million, consistent with the decline in service revenue.
Doctor and Embryologist professional fees: Decreased by Baht 7.14 million, consistent with the decline in service revenue.
Gross profit and Gross profit margin In the fourth quarter of 2025, the Company had a gross profit of Baht 33.92 million, a decrease of Baht 7.59 million or 18.29 percent compared to the fourth quarter of 2024, which had a gross profit of Baht 41.52 million. This also represented a decrease of Baht 5.46 million or 13.87 percent compared to the third quarter of 2025, which had a gross profit of Baht 39.39 million. The primary cause was the increase in cost of services as explained in the cost of services section. Consequently, the Company’s gross profit margin in the fourth quarter of 2025 was 41.77 percent, a decrease of 5.32 percent compared to the fourth quarter of 2024, which had a gross profit margin of 47.09 percent. It also decreased by 1.20 percent compared to the third quarter of 2025, which had a gross profit margin of 42.97 percent.
For the year 2025, the Company had a gross profit of Baht 147.16 million, a decrease of Baht 31.17 million or 17.48 percent compared to 2024, which had a gross profit of Baht 178.33 million. Meanwhile, the gross profit margin for 2025 was 41.69 percent, a decrease compared to 2024, which had a gross profit margin of 47.97 percent, representing a decrease of 6.28 percent. This was due to the increase in cost of services and the decrease in service revenue
Distribution costs In the fourth quarter of 2025, the Company’s distribution costs amounted to Baht 6.79 million, an increase of Baht 0.56 million or 8.94 percent compared to the fourth quarter of 2024, which had distribution costs of Baht 6.23 million. This increase was primarily due to advertising and public relations expenses, specifically the recognition of expenses under service exchange agreements for public relations by famous individuals who successfully received treatment with the Company, totaling Baht 2.25 million. This was offset by a decrease in employee-related expenses of Baht 0.90 million and a decrease in credit card fees of Baht 0.28 million. Distribution costs decreased by Baht 1.37 million or 16.78 percent compared to the third quarter of 2025, which had distribution costs of Baht 8.15 million, due to the adjustment of estimated bonus payments to employees.
For the year 2025, the Company had distribution costs of Baht 28.29 million, an increase of Baht 3.84 million or 15.69 percent compared to 2024, which had distribution costs of Baht 24.45 million. The primary reasons were:
Marketing employee expenses: Increased by Baht 2.55 million to support the operations of the Rama 9 International branch.
Advertising and public relations expenses: Increased by Baht 2.84 million from public relations expenses involving famous individuals who successfully received treatment with the Company.
Credit card fees: Decreased by Baht 1.95 million due to the decrease in service revenue.
Administrative expenses In the fourth quarter of 2025, the Company’s administrative expenses amounted to Baht 21.59 million, an increase of Baht 0.36 million or 1.72 percent compared to the fourth quarter of 2024, which had administrative expenses of Baht 21.23 million. This was due to:
Depreciation of buildings and building improvements increased by Baht 2.13 million.
Other expenses decreased by Baht 2.01 million from building repair costs and expenses for preparing the opening of the Rama 9 International branch, which decreased in 2025.International, which decreased in 2025.
Meanwhile, administrative expenses decreased by Baht 0.70 million or 3.14 percent compared to the third quarter of 2025, which had administrative expenses of Baht 22.29 million. This was due to a decrease in employee expenses of Baht 2.95 million, and an increase in other expenses of Baht 2.55 million from staff New Year party expenses and donations to the Siriraj Foundation and Sappasithiprasong Hospital by GFC Ubon Co., Ltd.
In 2025, the Company’s administrative expenses were Baht 85.85 million, an increase of Baht 24.75 million or 40.51 percent compared to 2024, which had administrative expenses of Baht 61.10 million. The primary reasons were:
Employee-related expenses: Increased by Baht 11.70 million due to the increase in the number of staff at the Rama 9 International branch.
Depreciation of buildings and building improvements: Increased by Baht 10.65 million from the Rama 9 International branch building.
Utility costs: Increased by Baht 2.95 million from utilities related to the Rama 9 International branch, such as electricity, security, and building maid staff expenses.
Financial costs In the fourth quarter of 2025, the Company’s finance costs amounted to Baht 0.49 million, representing a decrease of Baht 77.58 thousand or 13.61 percent compared to the fourth quarter of 2024, which had finance costs of Baht 0.57 million. Furthermore, finance costs decreased by Baht 3.36 thousand or 0.68 percent compared to the third quarter of 2025, which had finance costs of Baht 0.50 million.
For the year 2025, the Company had finance costs of Baht 2.04 million, an increase of Baht 0.29 million or 16.36 percent compared to 2024, which had finance costs of Baht 1.75 million. This increase was due to finance costs from long-term lease liabilities of GFC Ubon Co., Ltd.
Net profit and Net profit margin In the fourth quarter of 2025, the Company reported a net profit attributable to owners of the parent of Baht 3.50 million. This represents a decrease of Baht 7.27 million or 67.47 percent compared to the fourth quarter of 2024, which had a net profit attributable to owners of the parent of Baht 10.77 million. It also decreased by Baht 2.59 million or 42.53 percent compared to the third quarter of 2025, which had a net profit attributable to owners of the parent of Baht 6.10 million. Meanwhile, the net profit margin attributable to owners of the parent in the fourth quarter of 2025 was 4.31 percent, a decrease of 7.91 percent compared to the fourth quarter of 2024, which had a net profit margin attributable to owners of the parent of 12.22 percent. This margin also decreased by 2.34 percent compared to the third quarter of 2025, which had a net profit margin attributable to owners of the parent of 6.65 percent.
For the year 2025, the Company reported a net profit attributable to owners of the parent of Baht 22.40 million, a decrease of Baht 51.10 million or 69.52 percent compared to 2024, which had a net profit attributable to owners of the parent of Baht 73.51 million. At the same time, the net profit margin attributable to owners of the parent for the year 2025 was 6.35 percent, a decrease of 13.42 percent compared to 2024, which had a net profit margin attributable to owners of the parent of 19.77 percent.
Asset Management Capability
Financial Position Analysis
Assets
As of December 31, 2025, the Company had total assets of Baht 671.34 million, representing a decrease of Baht 54.26 million or 7.48 percent from December 31, 2024, with details as follows:

Current Assets
As of 31 December 2025, the Company’s current assets amounted to THB 158.43 million, representing a decrease of THB 23.86 million or 13.09% compared to 31 December 2024, primarily due to the following:
Cash and cash equivalents decreased by THB 27.56 million, mainly due to net cash used in investing activities amounting to THB 41.62 million, largely attributable to payments made for building improvement assets related to the Rama 9 International Branch, and net cash used in financing activities amounting to THB 49.79 million, such as dividend payments to shareholders.
Non-Current Assets
As of 31 December 2025, the Company’s non-current assets amounted to THB 512.91 million, representing a decrease of THB 30.40 million or 5.60% compared to 31 December 2024, primarily due to the following:
Property, plant and equipment decreased by THB 26.30 million, due to depreciation expenses for 2025.
Right-of-use assets decreased by THB 4.39 million, due to amortization expenses for 2025.
Liabilities
As of 31 December 2025, the Company’s total liabilities amounted to THB 81.67 million, representing a decrease of THB 42.32 million or 34.13% compared to 31 December 2024, with details as follows:

Current Liabilities
As of 31 December 2025, the Company’s current liabilities amounted to THB 57.21 million, representing a decrease of THB 37.03 million or 39.29% compared to 31 December 2024, primarily due to the following:
Trade and other current payables decreased by THB 32.70 million, mainly due to payments made to settle liabilities related to construction works and asset acquisitions, including the renovation of the Rama 9 International Branch, as well as the procurement of medical equipment and laboratory facilities for such branch.
Corporate income tax payable decreased by THB 7.40 million, due to a reduction in corporate income tax for 2025, which was attributable to a decline in net profit.
Non-Current Liabilities
As of 31 December 2025, the Company’s non-current liabilities amounted to THB 24.46 million, representing a decrease of THB 5.29 million or 17.80% compared to 31 December 2024, primarily due to the following:
Lease liabilities decreased by THB 5.60 million, resulting from lease payments made for office space during 2025.
Shareholders’ Equity

As of 31 December 2025, the Company’s shareholders’ equity amounted to THB 589.67 million, representing a decrease of THB 11.94 million or 1.98%. The decrease was primarily due to dividend payments totaling THB 39.62 million in 2025, partially offset by an increase from net profit for the period amounting to THB 27.61 million.
Cash Flows
For the year 2025, the Company reported a net decrease in cash and cash equivalents of THB 27.56 million. The Company had cash and cash equivalents at the beginning of the period of THB 158.31 million, resulting in cash and cash equivalents of THB 130.75 million as of 31 December 2025.
The details of cash flows from each activity are as follows:

Cash Flows from Operating Activities
The Company reported profit from operations before changes in operating assets and liabilities of THB 84.41 million. Cash generated from operating activities amounted to THB 76.44 million, with income tax payments during the period of THB 12.97 million and interest income of THB 0.38 million. As a result, as of 31 December 2025, the Company recorded net cash from operating activities of THB 63.85 million.
Cash Flows from Investing Activities
As of 31 December 2025, the Company had net cash used in investing activities of THB 41.62 million, primarily due to payments made to settle liabilities for building improvements and medical equipment for the Rama 9 International Branch, amounting to THB 40.85 million.
Cash Flows from Financing Activities
As of 31 December 2025, the Company had net cash used in financing activities of THB 49.79 million, mainly due to dividend payments to shareholders amounting to THB 40.62 million, and lease liability payments amounting to THB 9.18 million.
Key Financial Ratios
Liquidity Ratios

As at 31 December 2025, the Company recorded a current ratio of 2.77 times, representing an increase of 0.84 times from the ratio as at 31 December 2024. The increase was primarily attributable to a decrease in other current liabilities during the period.
Profitability Ratios

For the year 2025, the Company had an Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margin, an Earnings Before Interest and Taxes (EBIT) margin, and a Net Profit After Tax (NPAT) margin of 23.70 percent, 9.80 percent, and 7.78 percent, respectively. These represented decreases of 6.94 percent, 15.43 percent, and 11.87 percent compared to 2024. This was due to the decrease in service revenue and the increase in cost of services as mentioned in the performance analysis section.
Efficiency Ratios

As of December 31, 2025, the Company's Return on Assets (ROA) and Return on Fixed Assets were 4.98 percent and 6.68 percent, respectively. These ratios decreased compared to December 31, 2024, due to the decline in net profit.
Financial Policy Ratios

As of December 31, 2025, the Company’s Debt-to-Equity (D/E) Ratio was 0.14 times, a slight decrease compared to 0.21 times as of December 31, 2024.
The Company’s Dividend Payout Ratio as of December 31, 2025, was 269.70 percent, an increase of 198.29 percent compared to the dividend payout ratio of 71.41 percent as of December 31, 2024.
Dividend Payments
The 2025 Annual General Meeting of Shareholders, held on April 28, 2025, resolved to approve the dividend payment for the 2024 operating results at the rate of Baht 0.25 per share, totaling Baht 55 million. The Company had previously paid an interim dividend on September 13, 2024, at the rate of Baht 0.10 per share, totaling Baht 22 million. The remaining dividend to be paid was at the rate of Baht 0.15 per share, totaling Baht 33 million, which the Company scheduled for payment on May 27, 2025.
The Board of Directors' Meeting No. 6/2025, held on August 11, 2025, resolved to approve an interim dividend payment for the operating results from January 1, 2025, to June 30, 2025, at the rate of Baht 0.03 per share, totaling Baht 6.6 million. The Company scheduled this dividend payment by September 10, 2025.
The Board of Directors' Meeting No. 1/2026, held on February 23, 2026, resolved to propose to the Annual General Meeting of Shareholders, to be held on April 27, 2026, for consideration and approval of the dividend payment from the 2025 operating results at the rate of Baht 0.13 per share, totaling Baht 28.60 million. As the Company already paid an interim dividend for the operating results from January 1, 2025, to June 30, 2025, on September 10, 2025, at the rate of Baht 0.03 per share, totaling Baht 6.60 million (as mentioned in the second paragraph), the remaining dividend to be paid according to this shareholders' meeting resolution is at the rate of Baht 0.10 per share, totaling Baht 22 million.
Debt Securities with Financial Ratio Requirements
Debt Securities with Financial Ratio Requirements Issued?
No
Factors That May Affect Financial Condition
Factors or Incidents That May Materially Affect Financial Condition
Factors or events that may significantly impact financial position or operations
The Company recognizes the importance of managing risks and opportunities related to Environmental, Social, and Governance (ESG) issues, which may impact the organization's financial position, operational performance, or long-term value creation capability. ESG factors are linked to operations in terms of resource utilization, quality of medical services, legal compliance, and transparent corporate governance, which can affect stakeholder confidence. In 2025, the Company reviewed and identified key sustainability issues covering all three aspects of its operations.
Environmental Issues
The Company's operations involve relatively high consumption of electricity and resources, particularly in laboratories, medical equipment, and temperature control systems for egg and embryo storage, which are crucial processes in providing assisted reproductive technology services. Environmental issues that may affect the business include:
Energy consumption and increasing energy costs
Management of medical waste and laboratory chemicals
Risks from climate change that may affect infrastructure and operations
The Company recognizes the importance of efficient resource management coupled with minimizing environmental impact. It has implemented various projects and measures, such as reducing energy consumption, efficient water usage, sustainable waste management, and measures to reduce greenhouse gas emissions. The Company has established clear operational plans and targets for resource reduction, and communicates these guidelines to all levels of employees to ensure their awareness and continuous participation in environmental initiatives. Furthermore, it strictly adheres to environmental laws and regulations.
Social Issues
The Company's operations are directly related to service recipients/patients, making it crucial to manage social issues such as the safety of service recipients/patients, quality of treatment, and personal data protection. Social factors that may affect operations include:
Safety and standards of medical services
Protection of personal data of service recipients and medical information
Management of medical personnel and retention of specialized personnel
The Company conducts its business with social responsibility, continuously striving to improve the quality of treatment and service standards. It also prioritizes the protection of personal data for service recipients/patients in accordance with relevant laws and regulations. Furthermore, the Company encourages medical personnel to regularly receive training and develop their knowledge and expertise, as well as developing the potential of employees in all departments to support career advancement and create stability for the organization's personnel.
The Company considers the potential impacts of its operations on surrounding communities and society. It prioritizes community engagement, creating employment opportunities, and continuously supporting activities that enhance the quality of life in the community. This is to support business operations alongside sustainable social development.
Governance Issues
Good corporate governance is a crucial factor that builds stakeholder confidence and supports transparent and responsible business operations. Governance issues that may affect the Company include:
Compliance with laws and public health regulations
Internal Control and Enterprise Risk Management
Transparency in business operations and information disclosure
Prevention of Conflicts of Interest
The Company conducts its business adhering to principles of good corporate governance, transparency, accountability, and ethical operations, alongside respecting the human rights of all stakeholder groups. It has established risk management processes that cover all dimensions of its operations, enabling appropriate management of risks and opportunities that may arise from business activities. This supports the Company's stable and sustainable long-term growth.
Based on the aforementioned issues, the Company prioritizes integrating Environmental, Social, and Governance (ESG) risk management into its systematic enterprise risk management process. This enables the identification, assessment, and management of risks, as well as opportunities that may arise from business operations, in an appropriate and efficient manner. This approach also supports the Company's strategic decision-making, enhances stakeholder confidence, and promotes stable and sustainable business growth in the long term.
Demographic factors with declining birth rates
Thailand is facing a continuous decline in birth rates, leading to a decrease in newborns and a demographic shift towards an aging society. These factors could impact the Company's business in the long term, as the reproductive-age population base is projected to shrink. However, on the other hand, trends such as delayed marriages, increasing infertility rates, and the growing prevalence of assisted reproductive technologies may keep the demand for fertility medical services at a significant level.
To mitigate risks arising from these trends, the Company has adjusted its strategy by continuously focusing on improving the quality of treatment and service standards in assisted reproductive technology. This includes expanding access to services for infertile couples both domestically and internationally, as well as promoting the development of medical technology and innovations that enhance the chances of pregnancy. These efforts aim to support business growth and create sustainable value in the long term.

